Biofilms News and Research

RSS

Genta to supply Ganite for new CF clinical trial

Genta Incorporated announced that the Company will supply Ganite® (gallium nitrate injection) for a new clinical trial that will be initiated in patients with cystic fibrosis (CF) who may develop serious infections.

2 Dec 2009

Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, today announces that it has increased the current private placement offering (the "Offering"), first reported on November 16, 2009, from a maximum of 3,846,154 units to 4,335,500 Units, for total gross proceeds of up to $563,615.

27 Nov 2009

Novel way to fight UTIs: Research into Alzheimer's disease

Research into Alzheimer's disease seems an unlikely approach to yield a better way to fight urinary tract infections (UTIs), but that's what scientists at Washington University School of Medicine in St. Louis and elsewhere recently reported.

25 Nov 2009

Alzheimer's disease research leads to more effective UTI treatments

24 Nov 2009

Kane Biotech to raise $500,000 through private placement

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, today announces a non-brokered private placement offering for gross proceeds of up to $500,000 consisting of up to 3,846,154 units ("Units") at a price of $0.13 per Unit.

16 Nov 2009

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 7,597,895 entitled "Signal peptides, nucleic acid molecules and methods for treatment of caries" by the U.S. Patent and Trademark Office. This is the third patent to issue protecting Kane Biotech's CSP (Competence Stimulating Peptide) technology.

3 Nov 2009

Bacteria use a well-studied communication system to resist antibiotics

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

1 Nov 2009

Princeton University scientists and researchers team up to explore cancer evolution

Princeton University physical scientists will partner with researchers at four other institutions to explore the driving forces behind the evolution of cancer under a five-year, $15.2 million award from the National Cancer Institute.

27 Oct 2009

AGH Researchers to study the impact of biofilm infections on the success of orthopaedic procedures

Researchers from Allegheny General Hospital's (AGH) Department of Orthopaedic Surgery and Center for Genomic Sciences have launched dual groundbreaking studies that may help determine the cause of two common, hard-to-treat problems experienced by patients who undergo orthopedic surgery: a joint replacement that becomes infected and a bone fracture that will not heal properly.

24 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms is pleased to announce that a recent research publication from Princeton University reveals the genetic basis of poly-ß-1,6-N-acetylglucosamine (PNAG), the DispersinB® enzyme substrate, based biofilm formation in bacteria.

14 Oct 2009

Kane Biotech ends early exercise warrant incentive program

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms announces that the exercise period of the Company's early exercise warrant incentive program (the "Program") has ended. The Program was previously announced in the Company's press release dated August 6, 2009.

29 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

New hydrogel mats extends anti-infection protection

Treatment of hospital-related infections in the U.S. costs up to $11 billion a year and about half of those infections are related to medical devices implanted in patients. Until now, efforts to control drug-resistant biofilms on such devices have been largely unsuccessful.

15 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Study reveals that daily bathroom showers may deliver pathogenic bacteria

While daily bathroom showers provide invigorating relief and a good cleansing for millions of Americans, they also can deliver a face full of potentially pathogenic bacteria, according to a surprising new University of Colorado at Boulder study.

15 Sep 2009

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.

9 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Biologist demystifies Acinetobacter baumannii

Tao Weitao, a researcher in the College of Sciences' Department of Biology at the University of Texas at San Antonio is making great strides in a project that was funded one year ago by the San Antonio Area Foundation. The professor in the South Texas Center for Emerging Infectious Diseases is researching Acinetobacter baumannii, a soil-dwelling bacterium that threatens the health of military personnel in the Middle East and can also infect their family members once the soldiers have returned home following battle.

17 Aug 2009

New bio-hybrid materials could be used as sensors, catalysts, drug-delivery systems, more

Bacteria play a role in myriad industrial processes from fermentation to cleaning up environmental pollution. But floating freely in solution, the microbial cells constantly multiply, generating biomass that must be removed periodically, causing downtime. Additionally, the microorganisms cannot be localized to a specific region of interest.

3 Aug 2009

Biofilms News and Research

Genta to supply Ganite for new CF clinical trial

Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

Novel way to fight UTIs: Research into Alzheimer's disease

Alzheimer's disease research leads to more effective UTI treatments

Kane Biotech to raise $500,000 through private placement

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

Bacteria use a well-studied communication system to resist antibiotics

Princeton University scientists and researchers team up to explore cancer evolution

AGH Researchers to study the impact of biofilm infections on the success of orthopaedic procedures

Positive results from Transave's Phase II ARIKACE clinical trials

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

Kane Biotech ends early exercise warrant incentive program

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

New hydrogel mats extends anti-infection protection

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

Study reveals that daily bathroom showers may deliver pathogenic bacteria

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Biologist demystifies Acinetobacter baumannii

New bio-hybrid materials could be used as sensors, catalysts, drug-delivery systems, more

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News